Efficacy and Safety Study of Benralizumab for Patients With Severe Nasal Polyposis
Condition: Nasal Polyposis Interventions: Biological: Benralizumab 30 mg SC + Mometasone Furoate; Biological: Matching placebo SC + Mometasone Furoate Sponsor: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 17, 2018 Category: Research Source Type: clinical trials